Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  CardiovascularBG ControlIssue 730

High-normal A1c Signals CAD Risk in Nondiabetic Patients

Among patients who don't have diabetes, high-normal HbA1c levels (at or above 5.8%) are strongly correlated with the risk of coronary artery disease.... 

Advertisement

In what they described as the first large-scale study to assess the relationships among HbA1c, CAD, and carotid intima-medial thickness, researchers enrolled 1,703 consecutive patients undergoing either elective or urgent coronary angiography at a single medical center during a 5-year period. These nondiabetic patients were divided into tertiles according to their HbA1c levels: low (less than 5.5%), intermediate (5.5%-5.79%), or high (5.8% or higher), reported Dr. Monica Verdoia of the cardiology department, Maggiore della Carita Hospital, Novara (Italy), and her associates.

HbA1c was significantly associated in a dose-dependent fashion with the prevalence of CAD on angiography (odds ratio, 1.33). CAD prevalence was 66.9% in patients who had low-normal HbA1c, 73.7% in those with intermediate HbA1c, and 78.6% in those with high-normal HbA1c. This association remained robust after the data were adjusted to account for many confounding factors, including patient age and sex; the presence or absence of hypertension, hypercholesterolemia, renal failure, and previous myocardial infarction; and the use or nonuse of medications including angiotensin receptor blockers, beta-blockers, nitrates, statins, or diuretics, the investigators said.

This strong association between high-normal HbA1c and CAD prevalence persisted across every high-risk subgroup that was assessed. HbA1c also was independently and strongly associated with carotid intima-medial thickness and the prevalence of carotid plaques on ultrasonography.

The best cutoff value for predicting the presence of significant CAD was determined to be 5.8%. Even though this level is within the normal range, it "should be regarded as a risk factor for atherosclerosis," Dr. Verdoia and her associates said.

Further research is needed to confirm these findings and to assess whether more aggressive preventive strategies, such as lifestyle changes, the use of statins, or antiplatelet therapies, might reduce the development and progression of atherosclerosis in such patients, they added.

Practice Pearls:
  • The prevalence of CAD was 66.9% in nondiabetic patients who had low-normal HbA1c, 73.7% in those with intermediate HbA1c, and 78.6% in those with high-normal HbA1c.
  • A1c levels (at or above 5.8%) are strongly correlated with the risk of coronary artery disease

Am. J. Prev. Med. 2014 April 21 [doi: 10.1016/j.amepre.2014.02.002]).  

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 23 May, 2014 and appeared in  CardiovascularBG ControlIssue 730

Past five issues: Diabetes Clinical Mastery Series Issue 225 | Issue 765 | Diabetes Clinical Mastery Series Issue 224 | Issue 764 | Diabetes Clinical Mastery Series Issue 223 |

2014 Most Popular Articles:

Significant Weight Loss and Drop in A1c with New Combo of Lorcaserin and Phentermine
Posted January 16, 2015
ADA Issues New Standards of Medical Care for Diabetes
Posted January 02, 2015
Handbook of Diabetes, 4th Ed., Excerpt #25: Specific Circumstances that Affect Diabetes Control
Posted January 04, 2015
Dr. Timothy Garvey on Qsymia and Other New Therapies for Weight Loss
Posted January 12, 2015
New Guidelines Recommend Off-Loading to Increase Likelihood of Diabetic Foot Ulcer Healing
Posted December 26, 2014
New Guideline Released on Pharmacological Management of Obesity
Posted January 23, 2015
FDA Approves Weight-management Drug Saxenda
Posted December 26, 2014
For Your Patients: Practical Advice to Rev Up Your Workouts and Lower Fatigue
Posted January 09, 2015
Advancement in the Artificial Pancreas
Posted December 26, 2014
Phentermine and Topirimate ER (Qsymia) Studied for Type 2 Diabetes Patients
Posted January 15, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Will you prescribe inhaled insulin (Afrezza) when it becomes available this year?
CME/CE of the Week
Marie Williams, DPM

Category: Wound Care
Credits: .75



Search Articles On Diabetes In Control